The therapeutic impact of TSF on diabetes-associated myocardial fibrosis was related to the inhibitory effect of TGF-β/Smad and Wnt/β-catenin-mediated myocardial fibrosis (Figure 6). Here, TGFB1 is linked to diabetes mellitus.